Skip to Main content Skip to Navigation
Journal articles

Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement—A new target for lupus treatment

Nikaïa Smith 1, 2, * Mathieu Rodéro 2 Nassima Bekaddour 2 Vincent Bondet 3 Yasser Ruiz-Blanco 4 Mirja Harms 1 Benjamin Mayer 5 Brigitte Badder-Meunier 6, 7, 8 Pierre Quartier 6, 7, 8 Christine Bodemer 9 Véronique Baudouin 10 Yannick Dieudonné 11, 12, 13 Frank Kirchhoff 1 Elsa Sanchez Garcia 4 Bruno Charbit 14 Nicolas Leboulanger 7, 8 Bernd Jahrsdörfer 15 Yolande Richard 16, 8 Anne-Sophie Korganow 13, 11, 12 Jan Münch 1 Sébastien Nisole 17 Darragh Duffy 3, 14 Jean-Philippe Herbeuval 2, *
* Corresponding author
1 Universitätsklinikum Ulm - University Hospital of Ulm
2 LCBPT - UMR 8601 - Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques
3 Immunobiologie des Cellules dendritiques
4 Universität Duisburg-Essen [Essen]
5 Universität Ulm - Ulm University [Ulm, Allemagne]
6 IMAGINE - U1163 - Imagine - Institut des maladies génétiques
7 CHU Necker - Enfants Malades [AP-HP]
8 UPD5 - Université Paris Descartes - Paris 5
9 AP-HP Hôpital universitaire Robert-Debré [Paris]
10 Service de neuropédiatrie et maladies métaboliques [CHU Robert-Debré]
11 CHU Strasbourg
12 UNISTRA - Université de Strasbourg
13 ICT - Immunopathologie et chimie thérapeutique
14 CRT - Centre de Recherche Translationnelle
15 Institute of Transfusion Medicine and Immunogenetics
16 IC UM3 (UMR 8104 / U1016) - Institut Cochin
17 IRIM - Institut de Recherche en Infectiologie de Montpellier
Abstract : Type I interferons are highly potent cytokines essential for self-protection against tumors and infections. Deregulations of type I interferon signaling are associated with multiple diseases that require novel therapeutic options. Here, we identified the small molecule, IT1t, a previously described CXCR4 ligand, as a highly potent inhibitor of Toll-like receptor 7 (TLR7)-mediated inflammation. IT1t inhibits chemical (R848) and natural (HIV) TLR7-mediated inflammation in purified human plasmacytoid dendritic cells from blood and human tonsils. In a TLR7-dependent lupus-like model, in vivo treatment of mice with IT1t drives drastic reduction of both systemic inflammation and anti-double-stranded DNA autoantibodies and prevents glomerulonephritis. Furthermore, IT1t controls inflammation, including interferon α secretion, in resting and stimulated cells from patients with systemic lupus erythematosus. Our findings highlight a groundbreaking immunoregulatory property of CXCR4 signaling that opens new therapeutic perspectives in inflammatory settings and autoimmune diseases.
Document type :
Journal articles
Complete list of metadatas

Cited literature [76 references]  Display  Hide  Download
https://hal-pasteur.archives-ouvertes.fr/pasteur-02282952
Contributor : Marie-Christine Vougny <>
Submitted on : Tuesday, September 10, 2019 - 12:46:44 PM
Last modification on : Friday, October 23, 2020 - 4:58:06 PM
Long-term archiving on: : Saturday, February 8, 2020 - 12:12:22 AM

File

Vignette du document
eaav9019.full.pdf

Licence

Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Identifiers

Collections

PASTEUR | CNRS | UNIV-PARIS5 | BS | UNIV-MONTPELLIER | SITE-ALSACE | USPC | UNIV-PARIS | UP-SANTE | UP-SCIENCES

Citation

Nikaïa Smith, Mathieu Rodéro, Nassima Bekaddour, Vincent Bondet, Yasser Ruiz-Blanco, et al.. Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement—A new target for lupus treatment. Science Advances , American Association for the Advancement of Science (AAAS), 2019, 5 (7), pp.eaav9019. ⟨10.1126/sciadv.aav9019⟩. ⟨pasteur-02282952⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

437

Files downloads

814